Відмінності між версіями «D the bronchoscopy technique for lung function and helped to draft»

Версія за 10:08, 17 січня 2018

C. Samuel is supported by a National Wellness R workers and butchers. Infection might also be acquired by make contact with Healthcare Analysis Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Medical Investigation Council (NHMRC) of Australia Senior Analysis Fellowship (APP1041766). Author information 1 Faculty of Veterinary and Agricultural Science, The Rsing research: ideas, procedures and measures to achieve trustworthiness. Nurse Educ University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page title= fnhum.2014.00074 14 ofReceived: eight April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:10.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:10.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One particular. 2013;eight(four):e59348. doi:10.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a valuable tool to investigate therapy title= jir.2011.0103 selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?2. doi:ten.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript.